Fda accepts mesoblast's resubmission of the biologic license application for remestemcel-l in children with steroid-refractory acute graft versus host disease as a complete response and sets goal date of august 2, 2023

If approved, remestemcel-l will be the first allogeneic “off-the-shelf” cellular medicine in the us, and the first therapy for children under 12 years old with sr-agvhd. if approved, remestemcel-l will be the first allogeneic “off-the-shelf” cellular medicine in the us, and the first therapy for children under 12 years old with sr-agvhd.
MESO Ratings Summary
MESO Quant Ranking